how much of what we believe about amylin actually comes from co-agonism threads
Question in the title, detail here: how much of what we believe about amylin actually comes from co-agonism threads. Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from. Carried an assumption over from…
The engineering problem was duration: native amylin is short-acting and aggregation-prone. A long-acting analogue suitable for weekly administration is what makes the combination clinically interesting.
amylin and GLP-1 are not redundant pathways
Right, and the tolerability data in the combination arms is the part worth reading properly rather than summarising.
Not convinced. Amylin signalling is not a GLP-1 pathway and the mechanism you are proposing conflates them.
Agreed that the monotherapy numbers look modest out of context and that the context is the whole story.